![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
August 17, 2021
This study is evaluating two different screening strategies for non-cancerous pancreatic cysts; recently activated amendment #2 expands the eligibility criteria
August 17, 2021
A Standing Main Member of ECOG-ACRIN since 1972
July 7, 2021
This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
July 7, 2021
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
December 14, 2020
Lessons learned from our first virtual Group Meeting and a new leadership appointment
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma
December 14, 2020
October 23, 2020
The purpose of the Symposium is to introduce young investigators to ECOG-ACRIN and provide them with a forum to present their research in a formal manner and obtain feedback
October 20, 2020
What are the elements of a productive meeting when we get together – and what might they look like in a virtual format?